NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Jan 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Fluoride F-18 is a radioactive diagnostic agent administered intravenously for positron emission tomography (PET) imaging. It is used to detect bone metastases and assess skeletal integrity in oncology and orthopedic patients. The fluoride-18 isotope emits positrons that enable visualization of areas of abnormal bone metabolism.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team restructuring and shift toward cost management and retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate limited active hiring for this product, reflecting its mature lifecycle and approaching LOE. Career opportunities are concentrated in defensive strategies—market access, managed care, and regulatory maintenance—rather than growth-oriented roles.
Diagnostic Product ManagerMedical Science Liaison
Worked on SODIUM FLUORIDE F 18 at Imagin Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.